Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
Abstract Due to compromised homologous recombination (HR) repair, BRCA1‐ and BRCA2‐mutated tumours accumulate DNA damage and genomic rearrangements conducive of tumour progression. To identify drugs that target specifically BRCA2‐deficient cells, we screened a chemical library containing compounds i...
Main Authors: | Eliana MC Tacconi, Sophie Badie, Giuliana De Gregoriis, Timo Reisländer, Xianning Lai, Manuela Porru, Cecilia Folio, John Moore, Arnaud Kopp, Júlia Baguña Torres, Deborah Sneddon, Marcus Green, Simon Dedic, Jonathan W Lee, Ankita Sati Batra, Oscar M Rueda, Alejandra Bruna, Carlo Leonetti, Carlos Caldas, Bart Cornelissen, Laurent Brino, Anderson Ryan, Annamaria Biroccio, Madalena Tarsounas |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2019-07-01
|
Series: | EMBO Molecular Medicine |
Subjects: | |
Online Access: | https://doi.org/10.15252/emmm.201809982 |
Similar Items
-
The use of PARP inhibitor - olaparib for the treatment of ovarian cancer in clinical practice
by: S V Khokhlova
Published: (2016-12-01) -
PARP inhibitors in female reproductive system cancers
by: I A Pokataev, et al.
Published: (2017-06-01) -
Distinct implications of different BRCA mutations: efficacy of cytotoxic chemotherapy, PARP inhibition and clinical outcome in ovarian cancer
by: Hollis RL, et al.
Published: (2017-05-01) -
Successes and challenges of PARP inhibitors in cancer therapy
by: Tiffany K Ricks, et al.
Published: (2015-10-01) -
Advances in the use of PARP inhibitor therapy for breast cancer
by: Kelly E McCann, et al.
Published: (2018-08-01)